# A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma

> **NCT01969942** · PHASE1 · WITHDRAWN · sponsor: **University of Louisville**

## Conditions studied

- Ewing Sarcoma

## Interventions

- **BIOLOGICAL:** allogeneic stem cell transplantation
- **DRUG:** Clyclophosphamide
- **DRUG:** Fludarabina
- **DRUG:** Busulfan
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT01969942
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-04
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No subjects meeting study inclusion were enrolled.
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01969942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01969942, "A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01969942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*